Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current and future perspectives on fulvestrant.

William J Gradishar1, Tarek Sahmoud

  • 1Robert H. Lurie Comprehensive Cancer Center and NorthWestern University Feinberg School of Medicine, 676 North St. Clair Street, Chicago, IL 60611, USA. w-gradishar@northwestern.edu

Clinical Breast Cancer
|May 4, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ESR1 methylation and ESR1 mutations in circulating tumor cells (CTCs) and paired plasma-cfDNA of advanced breast cancer patients: A feasibility proof-of-concept study.

Molecular oncology·2026
Same author

The global cancer crisis: a review of growing burden, deepening inequality and initiatives for prevention and early detection.

Ecancermedicalscience·2026
Same author

Dual-positive CTCs in patients with advanced breast cancer show metastatic potential and prognostic value.

Science translational medicine·2026
Same author

Functional dysconnectivity in breast cancer patients undergoing hormone therapy.

Journal of clinical and experimental neuropsychology·2026
Same author

USP22 drives tumor immune evasion and checkpoint blockade resistance through EZH2-mediated epigenetic silencing of MHC-I.

The Journal of clinical investigation·2025
Same author

NCCN Guidelines® Insights: Breast Cancer, Version 5.2025.

Journal of the National Comprehensive Cancer Network : JNCCN·2025
Same journal

The Clinical Impact of Not Performing Axillary Lymph Node Dissection in pN+sn Breast Cancer Patients Undergoing Total Mastectomy.

Clinical breast cancer·2026
Same journal

Reducing Clip Migration in Mammographic-Guided Vacuum Assisted Biopsy With Direct Insertion of the UltraCor Twirl Clip Marker: A Quality Improvement Project.

Clinical breast cancer·2026
Same journal

Tracking Utilization of Neoadjuvant Endocrine Therapy (NET) and Neoadjuvant Chemotherapy (NCT) for Hormone Receptor-Positive Breast Cancer (HR + BC) in the U.S.A. Over Time - A TriNetX Database Study.

Clinical breast cancer·2026
Same journal

A Study on the Association Between Preventive Behaviors and Quality of Life in High-risk Populations for Postoperative Lymphedema Following Breast Cancer Surgery.

Clinical breast cancer·2026
Same journal

Prevalence and Prognostic Implications of Circulating Tumor Cells Among Patients Undergoing Neoadjuvant Chemotherapy for Early-Stage Breast Cancer.

Clinical breast cancer·2026
Same journal

Intraoperative Indocyanine Green Angiography as a Predictor of Complications in Breast Cancer Patients Undergoing Conservative Mastectomy.

Clinical breast cancer·2026
See all related articles

Fulvestrant is an effective estrogen receptor antagonist for postmenopausal women with hormone-sensitive breast cancer. Ongoing trials explore its use in various cancers and combinations, including with anastrozole.

Area of Science:

  • Oncology
  • Endocrinology

Background:

  • Fulvestrant is an estrogen receptor antagonist effective in postmenopausal women with hormone-sensitive breast cancer following antiestrogen therapy.
  • Its favorable safety and pharmacokinetic profile supports further clinical investigation.

Purpose of the Study:

  • To summarize the ongoing clinical development of fulvestrant.
  • To highlight its efficacy in breast cancer and exploration in other tumors.

Main Methods:

  • Review of numerous Phase II and III clinical trials evaluating fulvestrant.
  • Analysis of trials investigating fulvestrant in combination therapies and different cancer types.

Main Results:

  • Fulvestrant shows clinical activity after progression on nonsteroidal aromatase inhibitors.

Related Experiment Videos

  • Ongoing trials assess fulvestrant as first-line treatment for metastatic disease and in combination with targeted therapies.

    • Conclusions:

    • Fulvestrant is well-established in breast cancer treatment and is under extensive clinical development.
    • Early investigations are underway for its use in other solid tumors.